⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4940662 | 0.86 | USP2 (0.35) | — | |
| SCHEMBL60155 | 0.84 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL60063 | 0.84 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL4448677 | 0.80 | DNM1 (0.36) | — | |
| SCHEMBL8171362 | 0.71 | — | — | |
| SCHEMBL9006948 | 0.71 | TSHR (0.39) | — | |
| SCHEMBL17743428 | 0.69 | — | — | |
| SCHEMBL30454583 | 0.69 | TSHR (0.39) | — | |
| SCHEMBL378171 | 0.69 | — | — | |
| SCHEMBL28681827 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 928 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4385991-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| US-20240158439-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II HLA-DRB1*15:01 MOLECULES WITH ENHANCED METABOLIC STABILITY | PROVID PHARMACEUTICALS INC. | 2024-05-16 | — | — | US | disclosed |
| US-11976085-B2 | Process for producing ruthenium complexes and intermediates thereof and their use in olefin metathesis | Aperion Synthesis S.A. (PL) | 2024-05-07 | — | — | US | disclosed |
| CN-117881678-A | Compound with SHP2 protein degradation activity and medical application thereof | 尤比克斯治疗公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20240076308-A1 | PROCESS FOR PRODUCING RUTHENIUM COMPLEXES AND INTERMEDIATES THEREOF AND THEIR USE IN OLEFIN METATHESIS | APEIRON SYNTHESIS SA (PL) | 2024-03-07 | — | — | US | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| EP-4112053-B1 | TREATMENT OF SYNUCLEINOPATHIES | DEUTSCHES ZENTRUM FUER NEURODEGENERATIVE ERKRANKUNGEN E V DZNE (DE) | 2024-02-14 | — | — | EP | disclosed |
| EP-4308585-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II HLA-DRB1*15:01 MOLECULES WITH ENHANCED METABOLIC STABILITY | Provid Pharmaceuticals Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-01-18 | — | — | US | disclosed |
| WO-2024005556-A1 | Compounds, pharmaceutical compositions containing them and their medical use for the treatment or prevention of vascular diseases | VASTHERA CO., LTD. (KR) | 2024-01-04 | — | — | WO | disclosed |
| WO-2004009610-A2 | USE OF NUCLEOSIDE COMPOUNDS FOR NONSENSE SUPPRESSION AND THE TREATMENT OF GENETIC DISEASES | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009609-A2 | NUCLEOSIDE COMPOUNDS AND THEIR USE FOR TREATING CANCER AND DISEASES ASSOCIATED WITH SOMATIC MUTATIONS | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009563-A1 | 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR | INOTEK PHARMACEUTICALS CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009533-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004004774-A2 | COMPOSITIONS COMPRISING PANTHETINE FOR THE TREATMENT OF DYSLIPIDEMIA | ESPERION THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003105774-A2 | COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER, COMPOSITIONS THEREOF AND METHODS THEREWITH | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003102151-A2 | MODULATING CELL DIFFERENTIATION AND TREATING MYELOPROLIFERTIVE DISORDERS WITH JNK/MKK INHIBITORS | CELGENE CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003099221-A2 | METHODS FOR USING JNK INHIBITORS FOR TREATING OR PREVENTING DISEASE-RELATED WASTING | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003093236-A1 | 1-(PYRID-2-YL)-PIPERAZINE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR INHIBITOR | EURO-CELTIQUE, S.A. (LU) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003075917-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |